Rapt Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Rapt Therapeutics (RAPT) with a Buy rating and $6 price target The firm believes Rapt’s primary candidate, RPT904, operates through a commercially validated mechanism targeting immunoglobulin E, significantly reducing target risk given omalizumab approval in multiple indications, including food allergy, asthma, and chronic spontaneous urticaria.